Loading...
•
Jun 30, 2021
Jazz Pharmaceuticals Q2 2021 Earnings Report
Announced second quarter 2021 financial results and closed GW Pharmaceuticals plc Acquisition.
Key Takeaways
Jazz Pharmaceuticals announced a 34% increase in total revenues to $751.8 million compared to the second quarter of 2020. The company reaffirmed its 2021 total revenue guidance at $3.02 billion to $3.18 billion.
Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader
41% of Net Product Sales from Recently Launched or Acquired Products
Strong Xywav™ Adoption with 5,100 Active Patients Exiting the Second Quarter
FDA Approval and Launch of Rylaze™ in the U.S.
Revenue by Segment
Forward Guidance
Jazz Pharmaceuticals is reaffirming its previously communicated full year 2021 non-GAAP financial guidance and updating its 2021 GAAP guidance. This guidance reflects the Company's current and future expected operational performance, including COVID-19 related impacts, the strength of its underlying operations and the prioritization of new and ongoing value creating development projects.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...